Dallas, Texas (PRWEB) May 12, 2013
Analysis of global grant activity, scientific publication rates, and patent applications reveal that research activity involving mesenchymal stem cells increased 58% year-over-year from 2008 to 2009, and 112% from 2009 to 2010. Of most interest is that this rate of growth accelerated in 2011, making mesenchymal stem cells the fastest growing area of stem cell research.
Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.
Revealing Unique Strategic Opportunities & Unknown Competitive Advantages
MSCs are advantageous over other stem cells types for several reasons. First, they avoid the ethical issues that surround embryonic stem cell research. Second, repeated studies have found that human MSCs are immuno-privileged, and therefore, represent an advantageous cell type for allogenic transplantation, reducing the risks of rejection and complications of transplantation. Recently, there have also been significant advances in the use of autologous MSCs to regenerate human tissues, including cartilage and meniscus, tendons, and bone fractures.
This market research report focuses on recent advances in Mesenchymal stem cells research applications, explores research priorities by market segment, highlights individual labs and end-users of MSC research products, explores the competitive environment for MSC research products, and provides 5-year growth and trend analysis. The report advantageously pos
Copyright©2012 Vocus, Inc.
All rights reserved